Nancy Lin: Excited to see Translational Breast Cancer Research Consortium presentations at SABCS 2024
Nancy Lin, Breast cancer specialist at the Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School, shared on X:
“Excited to see these Translational Breast Cancer Research Consortium presentations at SABCS 2024!
-TBCRC 052: Does margetuximab provide benefit over trastuzumab in neoadjuvant HER2+ disease?
-TBCRC 056: neoadjuvant PARP + IO in ER+ BRCA1/2 or PALB2 mut breast cancer?
– and more!”
Dr. Nancy Lin, an American oncologist, serves at the Dana-Farber Cancer Institute and holds the position of Associate Professor of Medicine at Harvard Medical School. Focused on HER2 positive breast cancer, her research explores novel diagnostic methods and treatment modalities. Recognized for her contributions, she received the Breast Cancer Research Foundation Westchester Women’s Award in Memory of Marla Mehlman in 2007. Dr. Lin leads multiple clinical trials, advocating for targeted therapies in metastatic breast cancer patients.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023